{"entity":{"id":"caris","kind":"company","name":"Caris Life Sciences","aka":[],"tldr":"Whole-exome and whole-transcriptome tumour profiling at scale, with a large real-world database.","summary":"Caris Life Sciences, based in Irving, Texas, and listed as CAI after its 2025 IPO, performs whole-exome and whole-transcriptome tumour profiling at scale and holds a large real-world database. Its products are MI Profile, which combines exome and transcriptome sequencing, Caris Assure, a blood-based assay, and MI Cancer Seek, which received FDA approval in 2024. OnCo links it to comprehensive genomic profiling and whole-exome and whole-genome sequencing, and to ideas that every tumour genomic report should be machine-readable and should list open, nearby, matched trials. Whether whole-transcriptome data changes treatment decisions often enough to justify its cost over targeted panels is the open question. MI Cancer Seek has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.carislifesciences.com"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["cgp","wes-wgs","companion-diagnostic"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Irving, TX","country":"US","companyType":"diagnostics","website":"https://www.carislifesciences.com","ticker":"CAI","investors":[],"funding":[]},"route":"/companies/caris/","neighbours":{"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/"},{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"paper":[{"id":"paper-philip-kras-wild-type-pancreatic-ccr-2022","kind":"paper","name":"Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma","route":"/key-papers/paper-philip-kras-wild-type-pancreatic-ccr-2022/"},{"id":"paper-weinberg-biliary-profiling-jgo-2019","kind":"paper","name":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","route":"/key-papers/paper-weinberg-biliary-profiling-jgo-2019/"}],"idea":[{"id":"idea-data-structured-genomic-reports","kind":"idea","name":"Every tumour genomic report machine-readable and deposited nationally","route":"/ideas/idea-data-structured-genomic-reports/"},{"id":"idea-tr1-ngs-report-live-trial-match","kind":"idea","name":"Every tumour sequencing report lists open, nearby, matched trials pulled live","route":"/ideas/idea-tr1-ngs-report-live-trial-match/"}],"drug":[{"id":"caris-mi-cancer-seek","kind":"drug","name":"MI Cancer Seek","route":"/drugs/caris-mi-cancer-seek/"}]}}